Results 251 to 260 of about 456,798 (336)

Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis. [PDF]

J Clin Med
Casas Deza D, Polo Cuadro C, Gascón Ruiz M, Barreiro-de Acosta M, Mañosa M, Rodríguez-Moranta F, Zabana Y, Céspedes Martínez E, Ordás I, Miranda Bautista J, García MJ, García de la Filia Molina I, Roig Ramos C, Ruiz Cerulla A, Segarra-Ortega JX, Matallana Royo V, Rodríguez González E, Martínez de Juan F, Manceñido Marcos N, Madero Velázquez L, Betoré Glaría E, Álvarez Herrero B, Suris G, Garrido Marín A, Brunet Mas E, Alonso Abreu I, Santos Fernández J, Vaamonde Lorenzo M, Almingol Crespo C, Folguera C, Sanz Segura P, Moralejo Lozano Ó, López Couceiro L, Tejido Sandoval C, Mena Sánchez R, Sainz E, Marquès-Camí M, Ferreiro-Iglesias R, Ortega Moya SP, Wolfe García PM, Borras Garriga P, Herreros Martínez B, Calvo Iñiguez M, Frago Larramona S, Ladrón Abia P, Serra-Ruiz X, Menchén L, Rivas Rivas C, Mesonero Gismero F, Vicente Lidón R, Gutierrez A, García López S, GETECCU.   +52 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis. [PDF]

Hum Vaccin Immunother
Chen Y, Xu L, Zou S, Chen J, Xu X.
europepmc   +1 more source

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

The Lancet, 2018
J. Moslehi, J. Salem, J. Sosman, B. Lebrun-Vignes, Douglas B. Johnson   +4 more
semanticscholar   +1 more source

Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis

Advanced Science, EarlyView.
Proteolytic cleavage of the deubiquitinase CYLD emerges as a critical driver of autoimmune hepatitis. TNFα‐induced CYLD loss in macrophages amplifies S100A9‐triggered MAPK activation, leading to excessive chemokine production and hepatic inflammation. Pharmacological inhibition of MEK signaling effectively attenuates experimental disease, highlighting ...
Han Liu, Chen Su, Jianling Liu, Mingyan Xing, Xiaoxia Wu, Lingxia Wang, Xiaoming Zhao, Hanwen Zhang, YangYang Xie, YangYang Wang, Hong Li, Yu Li, Ming Li, Haibing Zhang   +13 more
wiley   +1 more source

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

Advanced Science, EarlyView.
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu, Chun‐Chieh Yeh, Tsai‐Chen Wu, Chia‐Hsin Lin, Yi‐Ting Kuo, Yoichiro Iwakura, Yuan‐Ji Day, Charles Drake, Vedran Radojcic, Ying‐Chyi Song, Heng‐Hsiung Wu, Hung‐Rong Yen   +11 more
wiley   +1 more source

Outcomes in Patients With Immune Checkpoint Inhibitor-Related Myopathy and Prolonged Follow-Up. [PDF]

Neurol Neuroimmunol Neuroinflamm
Segal Y, Mangioris G, Toledano M, Kottschade L, Flanagan EP, McKeon A, Stoff R, Naddaf E, Pittock SJ, Dubey D, Zekeridou A.   +10 more
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source